VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
2.000
+0.130 (6.96%)
Apr 25, 2025, 4:00 PM EDT - Market closed
VivoSim Labs Revenue
VivoSim Labs had revenue of $24.00K in the quarter ending December 31, 2024, with 380.00% growth. This brings the company's revenue in the last twelve months to $122.00K, down -49.59% year-over-year. In the fiscal year ending March 31, 2024, VivoSim Labs had annual revenue of $109.00K, down -70.54%.
Revenue (ttm)
$122.00K
Revenue Growth
-49.59%
P/S Ratio
19.40
Revenue / Employee
$6,100
Employees
20
Market Cap
3.40M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walmart | 680.99B |
Amazon.com | 637.96B |
Apple | 395.76B |
Berkshire Hathaway | 371.43B |
Alphabet | 350.02B |
Microsoft | 261.80B |
Meta Platforms | 164.50B |
NVIDIA | 130.50B |
VIVS News
- 1 day ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 2 days ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 23 days ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 4 weeks ago - Organovo Provides Business Update - GlobeNewsWire
- 4 weeks ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire
- 5 weeks ago - Organovo Announces Reverse Stock Split - GlobeNewsWire
- 6 weeks ago - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - GlobeNewsWire
- 7 weeks ago - Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - GlobeNewsWire